BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duffy M, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, Cardoso F. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). European Journal of Cancer 2017;75:284-98. [DOI: 10.1016/j.ejca.2017.01.017] [Cited by in Crossref: 220] [Cited by in F6Publishing: 197] [Article Influence: 44.0] [Reference Citation Analysis]
Number Citing Articles
1 Lenzo NP, Meyrick D, Turner JH. Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer. Diagnostics (Basel) 2018;8:E16. [PMID: 29439481 DOI: 10.3390/diagnostics8010016] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 12.3] [Reference Citation Analysis]
2 Nass N, Walter S, Jechorek D, Weissenborn C, Ignatov A, Haybaeck J, Sel S, Kalinski T. High neuronatin (NNAT) expression is associated with poor outcome in breast cancer. Virchows Arch 2017;471:23-30. [DOI: 10.1007/s00428-017-2154-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
3 Kern R, Correa SC, Scandolara TB, Carla da Silva J, Pires BR, Panis C. Current advances in the diagnosis and personalized treatment of breast cancer: lessons from tumor biology. Per Med 2020;17:399-420. [PMID: 32804054 DOI: 10.2217/pme-2020-0070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA 2019;321:288. [DOI: 10.1001/jama.2018.19323] [Cited by in Crossref: 727] [Cited by in F6Publishing: 681] [Article Influence: 242.3] [Reference Citation Analysis]
5 Salgado R, Solit DB, Rimm DL, Bogaerts J, Canetta R, Lively T, Lyerly K, Span PN, Bateman-House A, Makady A, Bergmann L, Nagai S, Smith C, Robson M, Savage M, Voest E, Sweeney C, Lambin P, Thomas M, Harris L, Lacombe D, Massard C; IBCD-Faculty. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. Eur J Cancer 2019;114:128-36. [PMID: 31060925 DOI: 10.1016/j.ejca.2019.03.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Aubele M, Schmitt M, Napieralski R, Paepke S, Ettl J, Absmaier M, Magdolen V, Martens J, Foekens JA, Wilhelm OG, Kiechle M. The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges. Dis Markers 2017;2017:4934608. [PMID: 29138528 DOI: 10.1155/2017/4934608] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
7 Jeong S, Park MJ, Song W, Kim HS. Current immunoassay methods and their applications to clinically used biomarkers of breast cancer. Clin Biochem 2020;78:43-57. [PMID: 32007438 DOI: 10.1016/j.clinbiochem.2020.01.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Ta HDK, Minh Xuan DT, Tang WC, Anuraga G, Ni YC, Pan SR, Wu YF, Fitriani F, Putri Hermanto EM, Athoillah M, Andriani V, Ajiningrum PS, Wang CY, Lee KH. Novel Insights into the Prognosis and Immunological Value of the SLC35A (Solute Carrier 35A) Family Genes in Human Breast Cancer. Biomedicines 2021;9:1804. [PMID: 34944621 DOI: 10.3390/biomedicines9121804] [Reference Citation Analysis]
9 Horgan D, Ciliberto G, Conte P, Baldwin D, Seijo L, Montuenga LM, Paz-Ares L, Garassino M, Penault-Llorca F, Galli F, Ray-Coquard I, Querleu D, Capoluongo E, Banerjee S, Riegman P, Kerr K, Horbach B, Büttner R, Van Poppel H, Bjartell A, Codacci-Pisanelli G, Westphalen B, Calvo F, Koeva-Balabanova J, Hall S, Paradiso A, Kalra D, Cobbaert C, Varea Menendez R, Maravic Z, Fotaki V, Bennouna J, Cauchin E, Malats N, Gutiérrez-Ibarluzea I, Gannon B, Mastris K, Bernini C, Gallagher W, Buglioni S, Kent A, Munzone E, Belina I, Van Meerbeeck J, Duffy M, Sarnowska E, Jagielska B, Mee S, Curigliano G. Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. Biomed Hub 2020;5:182-223. [PMID: 33564664 DOI: 10.1159/000511209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Nicolini A, Ferrari P, Rossi G, Carpi A. Tumour growth and immune evasion as targets for a new strategy in advanced cancer. Endocr Relat Cancer 2018;25:R577–R604. [PMID: 30306784 DOI: 10.1530/ERC-18-0142] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
11 Jeschke U, Zhang X, Kuhn C, Jalaguier S, Colinge J, Pfender K, Mayr D, Ditsch N, Harbeck N, Mahner S, Sixou S, Cavaillès V. The Prognostic Impact of the Aryl Hydrocarbon Receptor (AhR) in Primary Breast Cancer Depends on the Lymph Node Status. Int J Mol Sci 2019;20:E1016. [PMID: 30813617 DOI: 10.3390/ijms20051016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
12 Araz M, Beypinar I, Kazan S, Inci F, Celiker M, Uysal M. Are preoperative serum CA15-3 levels different in breast cancer subgroups? Current Problems in Cancer 2019;43:115-22. [DOI: 10.1016/j.currproblcancer.2018.06.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sixou S, Müller K, Jalaguier S, Kuhn C, Harbeck N, Mayr D, Engel J, Jeschke U, Ditsch N, Cavaillès V. Importance of RIP140 and LCoR Sub-Cellular Localization for Their Association With Breast Cancer Aggressiveness and Patient Survival. Transl Oncol 2018;11:1090-6. [PMID: 30007204 DOI: 10.1016/j.tranon.2018.06.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
14 Rivas J, Díaz N, Silva I, Morales D, Lavanderos B, Álvarez A, Saldías MP, Pulgar E, Cruz P, Maureira D, Flores G, Colombo A, Blanco C, Contreras HR, Jaña F, Gallegos I, Concha ML, Vergara-Jaque A, Poblete H, González W, Varela D, Trimmer JS, Cáceres M, Cerda O. KCTD5, a novel TRPM4-regulatory protein required for cell migration as a new predictor for breast cancer prognosis. FASEB J 2020;34:7847-65. [PMID: 32301552 DOI: 10.1096/fj.201901195RRR] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
15 Taouk G, Hussein O, Zekak M, Abouelghar A, Al-Sarraj Y, Abdelalim EM, Karam M. CD56 expression in breast cancer induces sensitivity to natural killer-mediated cytotoxicity by enhancing the formation of cytotoxic immunological synapse. Sci Rep 2019;9:8756. [PMID: 31217484 DOI: 10.1038/s41598-019-45377-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
16 Martínez-Pérez C, Turnbull AK, Dixon JM. The evolving role of receptors as predictive biomarkers for metastatic breast cancer. Expert Rev Anticancer Ther 2019;19:121-38. [PMID: 30501540 DOI: 10.1080/14737140.2019.1552138] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
17 Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, Ferree S, Sgroi D, Schnabel C, Baehner FL, Mallon E, Dowsett M. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018;4:545-553. [PMID: 29450494 DOI: 10.1001/jamaoncol.2017.5524] [Cited by in Crossref: 120] [Cited by in F6Publishing: 111] [Article Influence: 40.0] [Reference Citation Analysis]
18 Banys-Paluchowski M, Witzel I, Aktas B, Fasching PA, Hartkopf A, Janni W, Kasimir-Bauer S, Pantel K, Schön G, Rack B, Riethdorf S, Solomayer EF, Fehm T, Müller V. The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. Sci Rep 2019;9:2318. [PMID: 30783124 DOI: 10.1038/s41598-018-37259-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
19 Paquette M, Phoenix S, Lawson C, Guérin B, Lecomte R, Tai LH, Turcotte ÉE, Leyton JV. A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts. EJNMMI Res 2020;10:69. [PMID: 32592121 DOI: 10.1186/s13550-020-00656-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Palacios Calvo J, Albanell J, Rojo F, Ciruelos E, Aranda-López I, Cortés J, García-Caballero T, Martín M, López-García MÁ, Colomer R. [Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology]. Rev Esp Patol 2018;51:97-109. [PMID: 29602380 DOI: 10.1016/j.patol.2017.12.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Ovcaricek T, Takac I, Matos E. Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer. Radiol Oncol 2019;53:285-92. [PMID: 31553709 DOI: 10.2478/raon-2019-0038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
22 Maniez P, Osada M, Reix N, Mathelin C. [uPA/PAI-1 and EPClin®: Comparison of their impact on the management of intermediate-prognosis breast cancers]. Gynecol Obstet Fertil Senol 2021:S2468-7189(21)00248-8. [PMID: 34626849 DOI: 10.1016/j.gofs.2021.10.003] [Reference Citation Analysis]
23 de Moor JS, Gray SW, Mitchell SA, Klabunde CN, Freedman AN. Oncologist Confidence in Genomic Testing and Implications for Using Multimarker Tumor Panel Tests in Practice. JCO Precis Oncol 2020;4:PO. [PMID: 32923869 DOI: 10.1200/PO.19.00338] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: Past, present and future. Seminars in Cancer Biology 2018;52:56-73. [DOI: 10.1016/j.semcancer.2017.08.010] [Cited by in Crossref: 127] [Cited by in F6Publishing: 127] [Article Influence: 31.8] [Reference Citation Analysis]
25 Han JH, Park J, Seo YW, Kim TH. Designing a cancer therapeutic peptide by combining the mitochondrial targeting domain of Noxa and ErbB2-targeting moieties. FEBS Lett 2018;592:103-11. [PMID: 29193033 DOI: 10.1002/1873-3468.12922] [Reference Citation Analysis]
26 De Luca R, Profita G, Cicero G. Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life. Onco Targets Ther 2019;12:1621-7. [PMID: 30881017 DOI: 10.2147/OTT.S191519] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
27 Ji F, Xiao WK, Yang CQ, Yang M, Zhang LL, Gao HF, Lin YF, Zhu T, Cheng MY, Li WP, Pan WJ, Zhuang XS, Wang K. Tumor location of the central and nipple portion is associated with impaired survival for women with breast cancer. Cancer Manag Res 2019;11:2915-25. [PMID: 31040717 DOI: 10.2147/CMAR.S186205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
28 Almomen A, Arafah M, Alwhaibi M, Alsaigh N, Alshememry A, Alsaleh NB, Alrabeeah D, Al Saleh K, Alshamsan A, Alkholief M. Ceramide expression in relation to breast cancer molecular subtypes in Saudi women. Saudi Pharm J 2021;29:609-15. [PMID: 34194268 DOI: 10.1016/j.jsps.2021.04.022] [Reference Citation Analysis]
29 Li X, Liu L, Goodall GJ, Schreiber A, Xu T, Li J, Le TD. A novel single-cell based method for breast cancer prognosis. PLoS Comput Biol 2020;16:e1008133. [PMID: 32833968 DOI: 10.1371/journal.pcbi.1008133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Zarrinpar A, David Cheng TY, Huo Z. What Can We Learn About Drug Safety and Other Effects in the Era of Electronic Health Records and Big Data That We Would Not Be Able to Learn From Classic Epidemiology? J Surg Res 2020;246:599-604. [PMID: 31653413 DOI: 10.1016/j.jss.2019.09.053] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Falanga A, Marchetti M. Hemostatic biomarkers in cancer progression. Thromb Res 2018;164 Suppl 1:S54-61. [PMID: 29703485 DOI: 10.1016/j.thromres.2018.01.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
32 De Wilde RL, Devassy R, Torres-de la Roche LA, Krentel H, Tica V, Cezar C. Guidance and Standards for Breast Cancer Care in Europe. J Obstet Gynaecol India 2020;70:330-6. [PMID: 33041548 DOI: 10.1007/s13224-020-01316-6] [Reference Citation Analysis]
33 Oparina N, Erlandsson MC, Fäldt Beding A, Parris T, Helou K, Karlsson P, Einbeigi Z, Bokarewa MI. Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts. Cancers (Basel) 2021;13:2209. [PMID: 34064473 DOI: 10.3390/cancers13092209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Sestak I. Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy. Breast Care (Basel) 2017;12:146-51. [PMID: 28785181 DOI: 10.1159/000477795] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
35 Boonyaratanakornkit V, McGowan EM, Márquez-Garbán DC, Burton LP, Hamilton N, Pateetin P, Pietras RJ. Progesterone Receptor Signaling in the Breast Tumor Microenvironment. Adv Exp Med Biol 2021;1329:443-74. [PMID: 34664251 DOI: 10.1007/978-3-030-73119-9_21] [Reference Citation Analysis]
36 Liyanage PY, Hettiarachchi SD, Zhou Y, Ouhtit A, Seven ES, Oztan CY, Celik E, Leblanc RM. Nanoparticle-mediated targeted drug delivery for breast cancer treatment. Biochim Biophys Acta Rev Cancer 2019;1871:419-33. [PMID: 31034927 DOI: 10.1016/j.bbcan.2019.04.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 13.7] [Reference Citation Analysis]
37 Lewitowicz P, Matykiewicz J, Chrapek M, Koziel D, Horecka-Lewitowicz A, Gluszek-Osuch M, Wawrzycka I, Gluszek S. Tumor Digital Masking Allows Precise Patient Triaging: A Study Based on Ki-67 Scoring in Gastrointestinal Stromal Tumors. Scanning 2018;2018:7807416. [PMID: 30245762 DOI: 10.1155/2018/7807416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Cristofanilli M, Pierga J, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-arruda L, Ignatiadis M, Cabel L, van Laere SJ, Meier-stiegen F, Sandri M, Vidal-martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-rubio E, Krell J, Dawson S, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer E, Zorzino L, Darrigues L, Reis-filho JS, Gerratana L, Michiels S, Bidard F, Pantel K. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Critical Reviews in Oncology/Hematology 2019;134:39-45. [DOI: 10.1016/j.critrevonc.2018.12.004] [Cited by in Crossref: 95] [Cited by in F6Publishing: 89] [Article Influence: 31.7] [Reference Citation Analysis]
39 Ojo D, Rodriguez D, Wei F, Bane A, Tang D. Downregulation of CYB5D2 is associated with breast cancer progression. Sci Rep 2019;9:6624. [PMID: 31036830 DOI: 10.1038/s41598-019-43006-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
40 De Marchi T, Pyl PT, Sjöström M, Klasson S, Sartor H, Tran L, Pekar G, Malmström J, Malmström L, Niméus E. Proteogenomic Workflow Reveals Molecular Phenotypes Related to Breast Cancer Mammographic Appearance. J Proteome Res 2021;20:2983-3001. [PMID: 33855848 DOI: 10.1021/acs.jproteome.1c00243] [Reference Citation Analysis]
41 Wu HJ, Chu PY. Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer. Int J Mol Sci 2021;22:E636. [PMID: 33435254 DOI: 10.3390/ijms22020636] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Jardillier R, Chatelain F, Guyon L. Bioinformatics Methods to Select Prognostic Biomarker Genes from Large Scale Datasets: A Review. Biotechnol J 2018;13:1800103. [DOI: 10.1002/biot.201800103] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
43 Noratto G, Layosa MA, Lage NN, Atienza L, Ivanov I, Mertens-Talcott SU, Chew BP. Antitumor potential of dark sweet cherry sweet (Prunus avium) phenolics in suppressing xenograft tumor growth of MDA-MB-453 breast cancer cells. J Nutr Biochem 2020;84:108437. [PMID: 32615370 DOI: 10.1016/j.jnutbio.2020.108437] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
44 Tang L, Ma Z, Ishikawa Y, Matsushita H, Ishida T, Jingu K. Effect of radiotherapy after breast-conserving surgery in elderly patients with early breast cancer according to the AJCC 8th Edition Breast Cancer Staging System in Japan. Breast Cancer 2021;28:465-70. [PMID: 33141399 DOI: 10.1007/s12282-020-01181-1] [Reference Citation Analysis]
45 Marques CS, Soares M, Santos A, Correia J, Ferreira F. Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes. Oncotarget 2017;8:105775-89. [PMID: 29285291 DOI: 10.18632/oncotarget.22398] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
46 Rey-Vargas L, Mejía-Henao JC, Sanabria-Salas MC, Serrano-Gomez SJ. Effect of neoadjuvant therapy on breast cancer biomarker profile. BMC Cancer 2020;20:675. [PMID: 32682413 DOI: 10.1186/s12885-020-07179-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
47 Lightbody G, Haberland V, Browne F, Taggart L, Zheng H, Parkes E, Blayney JK. Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application. Brief Bioinform 2019;20:1795-811. [PMID: 30084865 DOI: 10.1093/bib/bby051] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 19.5] [Reference Citation Analysis]
48 Xin L, Liu YH, Martin TA, Jiang WG. The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint. World J Oncol 2017;8:34-40. [PMID: 29147432 DOI: 10.14740/wjon1019w] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
49 Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel) 2021;13:4287. [PMID: 34503097 DOI: 10.3390/cancers13174287] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Luangwattananun P, Junking M, Sujjitjoon J, Wutti-In Y, Poungvarin N, Thuwajit C, Yenchitsomanus PT. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy. Breast Cancer Res Treat 2021;186:25-36. [PMID: 33389403 DOI: 10.1007/s10549-020-06032-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
51 Lotan TL, Tomlins SA, Bismar TA, Van der Kwast TH, Grignon D, Egevad L, Kristiansen G, Pritchard CC, Rubin MA, Bubendorf L. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. Am J Surg Pathol 2020;44:e15-29. [PMID: 32044806 DOI: 10.1097/PAS.0000000000001450] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
52 Oda G, Nakagawa T, Uemura N, Mori H, Mori M, Fujioka T, Onishi I, Uetake H. Immediate breast reconstruction is oncologically safe for node-positive patients: Comparison using propensity score matching. Medicine (Baltimore) 2021;100:e27184. [PMID: 34516518 DOI: 10.1097/MD.0000000000027184] [Reference Citation Analysis]
53 Heesch A, Maurer J, Stickeler E, Beheshti M, Mottaghy FM, Morgenroth A. Development of Radiotracers for Breast Cancer-The Tumor Microenvironment as an Emerging Target. Cells 2020;9:E2334. [PMID: 33096754 DOI: 10.3390/cells9102334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
54 Finn RS, Cristofanilli M, Ettl J, Gelmon KA, Colleoni M, Giorgetti C, Gauthier E, Liu Y, Lu DR, Zhang Z, Bartlett CH, Slamon DJ, Turner NC, Rugo HS. Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. Breast Cancer Res Treat 2020;184:23-35. [PMID: 32783178 DOI: 10.1007/s10549-020-05782-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Haghbin M, Hashemi Tayer A, Kamravan M, Sotoodeh Jahromi A. Platelet-Derived Procoagulant Microparticles as Blood-based Biomarker of Breast Cancer. Asian Pac J Cancer Prev 2021;22:1573-9. [PMID: 34048188 DOI: 10.31557/APJCP.2021.22.5.1573] [Reference Citation Analysis]
56 Freitas M, Neves MMPS, Nouws HPA, Delerue-Matos C. Quantum dots as nanolabels for breast cancer biomarker HER2-ECD analysis in human serum. Talanta 2020;208:120430. [PMID: 31816682 DOI: 10.1016/j.talanta.2019.120430] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
57 Grillo PK, Győrffy B, Götte M. Prognostic impact of the glypican family of heparan sulfate proteoglycans on the survival of breast cancer patients. J Cancer Res Clin Oncol 2021;147:1937-55. [PMID: 33742285 DOI: 10.1007/s00432-021-03597-4] [Reference Citation Analysis]
58 Sapcharoen K, Sanguansermsri P, Yasothornsrikul S, Muisuk K, Srikummool M. Gene Combination of CD44 rs187116, CD133 rs2240688, NF-κB1 rs28362491 and GSTM1 Deletion as a Potential Biomarker in Risk Prediction of Breast Cancer in Lower Northern Thailand. Asian Pac J Cancer Prev 2019;20:2493-502. [PMID: 31450925 DOI: 10.31557/APJCP.2019.20.8.2493] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
59 Ahlgrén-Rimpiläinen AJ, Arffman M, Suvisaari J, Manderbacka K, Lumme S, Keskimäki I, Huovinen R, Pukkala E. Excess mortality from breast cancer in female breast cancer patients with severe mental illness. Psychiatry Res 2020;286:112801. [PMID: 32001004 DOI: 10.1016/j.psychres.2020.112801] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Jafari SH, Saadatpour Z, Salmaninejad A, Momeni F, Mokhtari M, Nahand JS, Rahmati M, Mirzaei H, Kianmehr M. Breast cancer diagnosis: Imaging techniques and biochemical markers. J Cell Physiol 2018;233:5200-13. [PMID: 29219189 DOI: 10.1002/jcp.26379] [Cited by in Crossref: 104] [Cited by in F6Publishing: 98] [Article Influence: 26.0] [Reference Citation Analysis]
61 Lænkholm A, Jensen M, Eriksen JO, Rasmussen BB, Knoop AS, Buckingham W, Ferree S, Schaper C, Nielsen TO, Haffner T, Kibøl T, Møller Talman M, Bak Jylling AM, Tabor TP, Ejlertsen B. PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor–Positive Early Breast Cancer. JCO 2018;36:735-40. [DOI: 10.1200/jco.2017.74.6586] [Cited by in Crossref: 46] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
62 Cueva Bañuelos JF, Rodríguez López C, Cortegoso Mosquera A, Palacios Ozores P, Curiel García T. Clinical Relevance and Therapeutic Application of CTCs in Advanced Breast Cancer. Adv Exp Med Biol 2020;1220:147-64. [PMID: 32304085 DOI: 10.1007/978-3-030-35805-1_10] [Reference Citation Analysis]
63 Laible M, Hartmann K, Gürtler C, Anzeneder T, Wirtz R, Weber S, Keller T, Sahin U, Rees M, Ramaswamy A. Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy. BMC Cancer 2019;19:694. [PMID: 31307414 DOI: 10.1186/s12885-019-5890-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
64 Arana Echarri A, Beresford M, Campbell JP, Jones RH, Butler R, Gollob KJ, Brum PC, Thompson D, Turner JE. A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling. Front Immunol 2020;11:616188. [PMID: 33597950 DOI: 10.3389/fimmu.2020.616188] [Reference Citation Analysis]
65 Martínez-Pérez C, Leung J, Kay C, Meehan J, Gray M, Dixon JM, Turnbull AK. The Signal Transducer IL6ST (gp130) as a Predictive and Prognostic Biomarker in Breast Cancer. J Pers Med 2021;11:618. [PMID: 34210062 DOI: 10.3390/jpm11070618] [Reference Citation Analysis]
66 Shekari Z, Zare HR, Falahati A. Dual assaying of breast cancer biomarkers by using a sandwich–type electrochemical aptasensor based on a gold nanoparticles–3D graphene hydrogel nanocomposite and redox probes labeled aptamers. Sensors and Actuators B: Chemical 2021;332:129515. [DOI: 10.1016/j.snb.2021.129515] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
67 Huber D, Voith von Voithenberg L, Kaigala G. Fluorescence in situ hybridization (FISH): History, limitations and what to expect from micro-scale FISH? Micro and Nano Engineering 2018;1:15-24. [DOI: 10.1016/j.mne.2018.10.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
68 Vanderpuye V, Dadzie MA, Huo D, Olopade OI. Assessment of Breast Cancer Management in Sub-Saharan Africa. JCO Glob Oncol 2021;7:1593-601. [PMID: 34843373 DOI: 10.1200/GO.21.00282] [Reference Citation Analysis]
69 Törnroos R, Tina E, Göthlin Eremo A. SLC7A5 is linked to increased expression of genes related to proliferation and hypoxia in estrogen‑receptor‑positive breast cancer. Oncol Rep 2022;47:17. [PMID: 34792178 DOI: 10.3892/or.2021.8228] [Reference Citation Analysis]
70 Sestak I. Risk stratification in early breast cancer in premenopausal and postmenopausal women: integrating genomic assays with clinicopathological features. Curr Opin Oncol 2019;31:29-34. [PMID: 30299292 DOI: 10.1097/CCO.0000000000000490] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
71 Voith von Voithenberg L, Fomitcheva Khartchenko A, Huber D, Schraml P, Kaigala GV. Spatially multiplexed RNA in situ hybridization to reveal tumor heterogeneity. Nucleic Acids Res 2020;48:e17. [PMID: 31853536 DOI: 10.1093/nar/gkz1151] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
72 Dieci MV, Guarneri V, Giarratano T, Mion M, Tortora G, De Rossi C, Gori S, Oliani C, Merlini L, Pasini F, Bonciarelli G, Griguolo G, Orvieto E, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer. Oncologist 2018;23:297-305. [PMID: 29133514 DOI: 10.1634/theoncologist.2017-0322] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
73 Luhtala S, Haapaniemi T, Staff S, Isola J. Fluoro-Chromogenic Labelling for Detection of MCM2 to Assess Proliferation Activity in HER2-amplified Breast Carcinomas. Appl Immunohistochem Mol Morphol 2020;28:175-86. [PMID: 30358612 DOI: 10.1097/PAI.0000000000000716] [Reference Citation Analysis]
74 Gopinath SCB, Perumal V, Xuan S. MicroRNA-155 complementation on a chemically functionalized dual electrode surface for determining breast cancer. 3 Biotech 2020;10:270. [PMID: 32523864 DOI: 10.1007/s13205-020-02261-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Wu AC, Mazor KM, Ceccarelli R, Loomer S, Lu CY. The Implementation Process for Pharmacogenomic Testing for Cancer-Targeted Therapies. J Pers Med 2018;8:E32. [PMID: 30275409 DOI: 10.3390/jpm8040032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
76 Aisyah S, Handharyani E, Bermawie N, Setiyono A. Effects of ethanol extract of curry leaves (Murraya koenigii) on HER2 and caspase-3 expression in rat model mammary carcinoma. Vet World 2021;14:1988-94. [PMID: 34566312 DOI: 10.14202/vetworld.2021.1988-1994] [Reference Citation Analysis]
77 Tian Z, Tang J, Liao X, Yang Q, Wu Y, Wu G. Identification of a 9-gene prognostic signature for breast cancer. Cancer Med 2020. [PMID: 33090721 DOI: 10.1002/cam4.3523] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Duffy MJ, Mcdermott EW, Crown J. Use of Multiparameter Tests for Identifying Women with Early Breast Cancer Who Do Not Need Adjuvant Chemotherapy. Clinical Chemistry 2017;63:804-6. [DOI: 10.1373/clinchem.2016.267161] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
79 Abrao Nemeir I, Saab J, Hleihel W, Errachid A, Jafferzic-Renault N, Zine N. The Advent of Salivary Breast Cancer Biomarker Detection Using Affinity Sensors. Sensors (Basel) 2019;19:E2373. [PMID: 31126047 DOI: 10.3390/s19102373] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
80 Terkelsen T, Krogh A, Papaleo E. CAncer bioMarker Prediction Pipeline (CAMPP)-A standardized framework for the analysis of quantitative biological data. PLoS Comput Biol 2020;16:e1007665. [PMID: 32176694 DOI: 10.1371/journal.pcbi.1007665] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
81 Saeed MEM, Breuer E, Hegazy MF, Efferth T. Retrospective study of small pet tumors treated with Artemisia annua and iron. Int J Oncol 2020;56:123-38. [PMID: 31789393 DOI: 10.3892/ijo.2019.4921] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
82 Yoneten KK, Kasap M, Akpinar G, Gunes A, Gurel B, Utkan NZ. Comparative Proteome Analysis of Breast Cancer Tissues Highlights the Importance of Glycerol-3-phosphate Dehydrogenase 1 and Monoacylglycerol Lipase in Breast Cancer Metabolism. Cancer Genomics Proteomics 2019;16:377-97. [PMID: 31467232 DOI: 10.21873/cgp.20143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
83 Stewart RL, Updike KL, Factor RE, Henry NL, Boucher KM, Bernard PS, Varley KE. A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer. Cancer Res 2019;79:3466-78. [PMID: 31048497 DOI: 10.1158/0008-5472.CAN-18-3014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
84 Contreras-Espinosa L, Alcaraz N, De La Rosa-Velázquez IA, Díaz-Chávez J, Cabrera-Galeana P, Vega RR, Reynoso-Noveron N, Maldonado-Martínez HA, González-Barrios R, Montiel-Manríquez R, Bautista-Sánchez D, Castro-Hernández C, Álvarez-Gómez RM, Jiménez-Trejo F, Tapia-Rodríguez M, García-Gordillo J, Pérez-Rosas A, Bargallo-Rocha E, Arriaga-Canon C, Herrera LA. Transcriptome Analysis Identifies GATA3-AS1 as a Long Noncoding RNA Associated with Resistance to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients. J Mol Diagn 2021:S1525-1578(21)00238-5. [PMID: 34358678 DOI: 10.1016/j.jmoldx.2021.07.014] [Reference Citation Analysis]
85 Yu J, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Chen X, Shen K. A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age. J Transl Med 2021;19:75. [PMID: 33593381 DOI: 10.1186/s12967-021-02743-3] [Reference Citation Analysis]
86 Lu J, Hu F, Zhou Y. NR3C2-Related Transcriptome Profile and Clinical Outcome in Invasive Breast Carcinoma. Biomed Res Int 2021;2021:9025481. [PMID: 33564687 DOI: 10.1155/2021/9025481] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
87 Block I, Burton M, Sørensen KP, Andersen L, Larsen MJ, Bak M, Cold S, Thomassen M, Tan Q, Kruse TA. Association of miR-548c-5p, miR-7-5p, miR-210-3p, miR-128-3p with recurrence in systemically untreated breast cancer. Oncotarget 2018;9:9030-42. [PMID: 29507672 DOI: 10.18632/oncotarget.24088] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
88 Bulte JP, Simsek D, Bult P, de Wilt JHW, Strobbe LJA. Trends in pre-operative needle biopsy use in invasive breast cancer diagnosis: a Dutch nationwide population study. Acta Oncol 2020;59:1469-73. [PMID: 33030998 DOI: 10.1080/0284186X.2020.1830168] [Reference Citation Analysis]
89 Ye F, Wen J, Yang A, Wang Y, Li N, Yu P, Wei W, Tang J. The Influence of Hormone Therapy on secondary diabetes mellitus in Breast Cancer: A Meta-analysis. Clin Breast Cancer 2021:S1526-8209(21)00174-9. [PMID: 34429242 DOI: 10.1016/j.clbc.2021.06.014] [Reference Citation Analysis]
90 Roy-Luzarraga M, Abdel-Fatah T, Reynolds LE, Clear A, Taylor JG, Gribben JG, Chan S, Jones L, Hodivala-Dilke K. Association of Low Tumor Endothelial Cell pY397-Focal Adhesion Kinase Expression With Survival in Patients With Neoadjuvant-Treated Locally Advanced Breast Cancer. JAMA Netw Open 2020;3:e2019304. [PMID: 33107920 DOI: 10.1001/jamanetworkopen.2020.19304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Brandão M, Pondé N, Piccart-Gebhart M. Mammaprint™: a comprehensive review. Future Oncol 2019;15:207-24. [PMID: 30156427 DOI: 10.2217/fon-2018-0221] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
92 Fiorino S, Di Saverio S, Leandri P, Tura A, Birtolo C, Silingardi M, de Biase D, Avisar E. The role of matricellular proteins and tissue stiffness in breast cancer: a systematic review. Future Oncology 2018;14:1601-27. [DOI: 10.2217/fon-2017-0510] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
93 Yancey SW, Keene ON, Albers FC, Ortega H, Bates S, Bleecker ER, Pavord I. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol 2017;140:1509-18. [PMID: 29221581 DOI: 10.1016/j.jaci.2017.10.005] [Cited by in Crossref: 93] [Cited by in F6Publishing: 95] [Article Influence: 18.6] [Reference Citation Analysis]
94 Gouri A, Benarba B, Dekaken A, Aoures H, Benharkat S. Prediction of Late Recurrence and Distant Metastasis in Early-stage Breast Cancer: Overview of Current and Emerging Biomarkers. Curr Drug Targets 2020;21:1008-25. [PMID: 32164510 DOI: 10.2174/1389450121666200312105908] [Reference Citation Analysis]
95 Pershina O, Ermakova N, Pakhomova A, Widera D, Pan E, Zhukova M, Slonimskaya E, Morozov SG, Kubatiev A, Dygai A, Skurikhin EG. Cancer Stem Cells and Somatic Stem Cells as Potential New Drug Targets, Prognosis Markers, and Therapy Efficacy Predictors in Breast Cancer Treatment. Biomedicines 2021;9:1223. [PMID: 34572409 DOI: 10.3390/biomedicines9091223] [Reference Citation Analysis]
96 Nasrazadani A, Thomas RA, Oesterreich S, Lee AV. Precision Medicine in Hormone Receptor-Positive Breast Cancer. Front Oncol 2018;8:144. [PMID: 29780747 DOI: 10.3389/fonc.2018.00144] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
97 Ahn SK, Jung SY. Current Biomarkers for Precision Medicine in Breast Cancer. Adv Exp Med Biol 2021;1187:363-79. [PMID: 33983588 DOI: 10.1007/978-981-32-9620-6_18] [Reference Citation Analysis]
98 Freitas M, Nouws HP, Keating E, Delerue-matos C. High-performance electrochemical immunomagnetic assay for breast cancer analysis. Sensors and Actuators B: Chemical 2020;308:127667. [DOI: 10.1016/j.snb.2020.127667] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
99 Schick J, Ritchie RP, Restini C. Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. Breast Cancer (Auckl) 2021;15:1178223421995854. [PMID: 33994789 DOI: 10.1177/1178223421995854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
100 Hartmann K, Schlombs K, Laible M, Gürtler C, Schmidt M, Sahin U, Lehr HA. Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue. Diagn Pathol 2018;13:83. [PMID: 30342538 DOI: 10.1186/s13000-018-0760-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
101 Bense RD, Qiu SQ, de Vries EGE, Schröder CP, Fehrmann RSN. Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer. Cancer Treat Rev 2018;70:118-26. [PMID: 30149225 DOI: 10.1016/j.ctrv.2018.07.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
102 Merry E, Thway K, Jones RL, Huang PH. Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas. NPJ Precis Oncol 2021;5:17. [PMID: 33674685 DOI: 10.1038/s41698-021-00157-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
103 Crocetti E, Ravaioli A, Amadori D, Mancini S, Vattiato R, Giuliani O, Baldacchini F, Falcini F. Female breast cancers (T1-2, N0, M0, HR+, HER2-) with an intermediate genetic-based recurrence risk: a real-world estimate in Italy. Tumori 2019;105:483-7. [PMID: 31088341 DOI: 10.1177/0300891619849291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
104 Shao N, Xie C, Shi Y, Ye R, Long J, Shi H, Shan Z, Thompson AM, Lin Y. Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: a Surveillance, Epidemiology and End Results (SEER) Analysis. Cancer Manag Res 2019;11:1433-42. [PMID: 30863154 DOI: 10.2147/CMAR.S185212] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
105 Bodén ACS, Molin J, Garvin S, West RA, Lundström C, Treanor D. The human-in-the-loop: an evaluation of pathologists' interaction with artificial intelligence in clinical practice. Histopathology 2021;79:210-8. [PMID: 33590577 DOI: 10.1111/his.14356] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Giridhar KV, Liu MC. Use of Multigene Prognostic Indices to Guide Clinical Decision-Making Regarding Adjuvant Systemic Therapy. Curr Breast Cancer Rep 2018;10:251-61. [DOI: 10.1007/s12609-018-0297-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
107 Odularu AT, Ajibade PA, Mbese JZ. Impact of Molybdenum Compounds as Anticancer Agents. Bioinorg Chem Appl 2019;2019:6416198. [PMID: 31582964 DOI: 10.1155/2019/6416198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
108 Tan W, Yang M, Yang H, Zhou F, Shen W. Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers. Cancer Manag Res 2018;10:4333-47. [PMID: 30349367 DOI: 10.2147/CMAR.S174435] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
109 Tang L, Ishikawa Y, Matsushita H, Jingu K. Prognostic value of the AJCC 8th edition staging system for Japanese patients treated with surgery followed by radiotherapy for breast cancer. Int J Clin Oncol 2020;25:1499-505. [PMID: 32356049 DOI: 10.1007/s10147-020-01686-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
110 Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2019;30:1194-220. [PMID: 31161190 DOI: 10.1093/annonc/mdz173] [Cited by in Crossref: 320] [Cited by in F6Publishing: 286] [Article Influence: 160.0] [Reference Citation Analysis]
111 Juratli MA, Struecker B, Katou S, Morguel MH, Pascher A. [Influence of molecular pathology on oncological surgery of liver and bile duct tumors]. Chirurg 2021;92:1003-10. [PMID: 34519849 DOI: 10.1007/s00104-021-01495-6] [Reference Citation Analysis]
112 Singal AG, Hoshida Y, Pinato DJ, Marrero J, Nault JC, Paradis V, Tayob N, Sherman M, Lim YS, Feng Z, Lok AS, Rinaudo JA, Srivastava S, Llovet JM, Villanueva A. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology 2021;160:2572-84. [PMID: 33705745 DOI: 10.1053/j.gastro.2021.01.233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
113 Dalag L, Fergus JK, Zangan SM. Lung and Abdominal Biopsies in the Age of Precision Medicine. Semin Intervent Radiol 2019;36:255-63. [PMID: 31435134 DOI: 10.1055/s-0039-1693121] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
114 Yamaga I, Kawaguchi-Sakita N, Asao Y, Matsumoto Y, Yoshikawa A, Fukui T, Takada M, Kataoka M, Kawashima M, Fakhrejahani E, Kanao S, Nakayama Y, Tokiwa M, Torii M, Yagi T, Sakurai T, Haga H, Togashi K, Shiina T, Toi M. Vascular branching point counts using photoacoustic imaging in the superficial layer of the breast: A potential biomarker for breast cancer. Photoacoustics 2018;11:6-13. [PMID: 30003041 DOI: 10.1016/j.pacs.2018.06.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
115 Ghaderi F, Ahmadvand S, Ramezani A, Montazer M, Ghaderi A. Production and characterization of monoclonal antibody against a triple negative breast cancer cell line. Biochem Biophys Res Commun 2018;505:181-6. [PMID: 30243716 DOI: 10.1016/j.bbrc.2018.09.087] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
116 Mueller C, Haymond A, Davis JB, Williams A, Espina V. Protein biomarkers for subtyping breast cancer and implications for future research. Expert Rev Proteomics 2018;15:131-52. [PMID: 29271260 DOI: 10.1080/14789450.2018.1421071] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
117 Silva C, Perestrelo R, Silva P, Tomás H, Câmara JS. Breast Cancer Metabolomics: From Analytical Platforms to Multivariate Data Analysis. A Review. Metabolites 2019;9:E102. [PMID: 31121909 DOI: 10.3390/metabo9050102] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
118 Zabotina TN, Korotkova OV, Chertkova AI, Zakharova EN, Tabakov DV, Dzhgamadze NT, Savostikova MV, Artamonova EV, Khailenko VA, Kovalenko EI, Kadagidze ZG. Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters. Bull Exp Biol Med 2018;166:241-4. [PMID: 30488197 DOI: 10.1007/s10517-018-4323-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
119 Alfarsi LH, Ansari RE, Craze ML, Toss MS, Masisi B, Ellis IO, Rakha EA, Green AR. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. Breast Cancer Res Treat 2019;178:535-44. [DOI: 10.1007/s10549-019-05420-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
120 Zubor P, Kubatka P, Dankova Z, Gondova A, Kajo K, Hatok J, Samec M, Jagelkova M, Krivus S, Holubekova V, Bujnak J, Laucekova Z, Zelinova K, Stastny I, Nachajova M, Danko J, Golubnitschaja O. miRNA in a multiomic context for diagnosis, treatment monitoring and personalized management of metastatic breast cancer. Future Oncology 2018;14:1847-67. [DOI: 10.2217/fon-2018-0061] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
121 Hernández-arteaga AC, de Jesús Zermeño-nava J, Martínez-martínez MU, Hernández-cedillo A, Ojeda-galván HJ, José-yacamán M, Navarro-contreras HR. Determination of Salivary Sialic Acid Through Nanotechnology: A Useful Biomarker for the Screening of Breast Cancer. Archives of Medical Research 2019;50:105-10. [DOI: 10.1016/j.arcmed.2019.05.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
122 Tseng YJ, Huang CE, Wen CN, Lai PY, Wu MH, Sun YC, Wang HY, Lu JJ. Predicting breast cancer metastasis by using serum biomarkers and clinicopathological data with machine learning technologies. Int J Med Inform 2019;128:79-86. [PMID: 31103449 DOI: 10.1016/j.ijmedinf.2019.05.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 9.3] [Reference Citation Analysis]
123 Lebok P, Bönte H, Kluth M, Möller-Koop C, Witzel I, Wölber L, Paluchowski P, Wilke C, Heilenkötter U, Müller V, Schmalfeldt B, Simon R, Sauter G, Terracciano L, Krech RH, von der Assen A, Burandt E. 6q deletion is frequent but unrelated to patient prognosis in breast cancer. Breast Cancer 2021. [PMID: 34625909 DOI: 10.1007/s12282-021-01301-5] [Reference Citation Analysis]
124 Bartlett JMS, Sgroi DC, Treuner K, Zhang Y, Ahmed I, Piper T, Salunga R, Brachtel EF, Pirrie SJ, Schnabel CA, Rea DW. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial. Ann Oncol 2019;30:1776-83. [PMID: 31504126 DOI: 10.1093/annonc/mdz289] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 13.5] [Reference Citation Analysis]
125 Duffy MJ, Mcdermott EW, Crown J. Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA. Tumour Biol 2018;40:101042831877616. [DOI: 10.1177/1010428318776169] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
126 Pang H, Zhang G, Yan N, Lang J, Liang Y, Xu X, Cui Y, Wu X, Li X, Shan M, Wang X, Meng X, Liu J, Tian G, Cai L, Yuan D, Wang X. Evaluating the Risk of Breast Cancer Recurrence and Metastasis After Adjuvant Tamoxifen Therapy by Integrating Polymorphisms in Cytochrome P450 Genes and Clinicopathological Characteristics. Front Oncol 2021;11:738222. [PMID: 34868931 DOI: 10.3389/fonc.2021.738222] [Reference Citation Analysis]
127 Walter V, Fischer C, Deutsch TM, Ersing C, Nees J, Schütz F, Fremd C, Grischke EM, Sinn P, Brucker SY, Schneeweiss A, Hartkopf AD, Wallwiener M. Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer. Breast Cancer Res Treat 2020;183:137-44. [PMID: 32613540 DOI: 10.1007/s10549-020-05746-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
128 Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E, Farahmand L. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol 2020;84:106535. [PMID: 32361569 DOI: 10.1016/j.intimp.2020.106535] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
129 Surov A, Clauser P, Chang YW, Li L, Martincich L, Partridge SC, Kim JY, Meyer HJ, Wienke A. Can diffusion-weighted imaging predict tumor grade and expression of Ki-67 in breast cancer? A multicenter analysis. Breast Cancer Res 2018;20:58. [PMID: 29921323 DOI: 10.1186/s13058-018-0991-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
130 Benedetti R, Dell'Aversana C, Giorgio C, Astorri R, Altucci L. Breast Cancer Vaccines: New Insights. Front Endocrinol (Lausanne) 2017;8:270. [PMID: 29081765 DOI: 10.3389/fendo.2017.00270] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
131 Abdel-Fatah TMA, Broom RJ, Lu J, Moseley PM, Huang B, Li L, Liu S, Chen L, Ma RZ, Cao W, Wang X, Li Y, Perry JK, Aleskandarany M, Nolan CC, Rakha EA, Lobie PE, Chan SYT, Ellis IO, Hwang LA, Lane DP, Green AR, Liu DX. SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment. Br J Cancer 2019;120:728-45. [PMID: 30816325 DOI: 10.1038/s41416-019-0405-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
132 Falanga A, Marchetti M, Russo L. Hemostatic Biomarkers and Cancer Prognosis: Where Do We Stand? Semin Thromb Hemost 2021;47:962-71. [PMID: 34450680 DOI: 10.1055/s-0041-1733925] [Reference Citation Analysis]
133 Cheng LH, Hsu TC, Lin C. Integrating ensemble systems biology feature selection and bimodal deep neural network for breast cancer prognosis prediction. Sci Rep 2021;11:14914. [PMID: 34290286 DOI: 10.1038/s41598-021-92864-y] [Reference Citation Analysis]
134 Alfarsi L, Johnston S, Liu DX, Rakha E, Green AR. Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer. Histopathology 2018;73:545-58. [PMID: 29603357 DOI: 10.1111/his.13523] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
135 Lindgren M, Jansson M, Tavelin B, Dirix L, Vermeulen P, Nyström H. Type IV collagen as a potential biomarker of metastatic breast cancer. Clin Exp Metastasis 2021;38:175-85. [PMID: 33655422 DOI: 10.1007/s10585-021-10082-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 van Dooijeweert C, Deckers IAG, Baas IO, van der Wall E, van Diest PJ. Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands. Breast Cancer Res Treat 2019;175:487-97. [PMID: 30825048 DOI: 10.1007/s10549-019-05180-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
137 Horii R, Tsuda H, Masuda S, Sugita H, Togashi K, Ohno S, Akiyama F. Performance analysis of the anti-Ki67 antibody clone 30-9 for immunohistochemical staining of breast cancer. Breast Cancer 2020;27:1058-64. [PMID: 32440959 DOI: 10.1007/s12282-020-01108-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Liu CY, Huang CC, Tsai YF, Chao TC, Lien PJ, Lin YS, Feng CJ, Chen JL, Chen YJ, Chiu JH, Hsu CY, Tseng LM. VGH-TAYLOR: Comprehensive precision medicine study protocol on the heterogeneity of Taiwanese breast cancer patients. Future Oncol 2021. [PMID: 34665002 DOI: 10.2217/fon-2021-0131] [Reference Citation Analysis]
139 De Palma FDE, Del Monaco V, Pol JG, Kremer M, D’argenio V, Stoll G, Montanaro D, Uszczyńska-ratajczak B, Klein CC, Vlasova A, Botti G, D’aiuto M, Baldi A, Guigó R, Kroemer G, Maiuri MC, Salvatore F. The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome. Pharmacological Research 2020;161:105249. [DOI: 10.1016/j.phrs.2020.105249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
140 Trooboff SW, Kang R, Margenthaler J, Wong SL. Choosing Wisely: Optimizing Routine Workup for the Newly Diagnosed Breast Cancer Patient. Curr Breast Cancer Rep 2018;10:62-73. [DOI: 10.1007/s12609-018-0268-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
141 van Barele M, Heemskerk-Gerritsen BAM, Louwers YV, Vastbinder MB, Martens JWM, Hooning MJ, Jager A. Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm? Cancers (Basel) 2021;13:2506. [PMID: 34063736 DOI: 10.3390/cancers13112506] [Reference Citation Analysis]
142 Boersma YL. Advances in the Application of Designed Ankyrin Repeat Proteins (DARPins) as Research Tools and Protein Therapeutics. Methods Mol Biol 2018;1798:307-27. [PMID: 29868969 DOI: 10.1007/978-1-4939-7893-9_23] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
143 Souza KCB, Evangelista AF, Leal LF, Souza CP, Vieira RA, Causin RL, Neuber AC, Pessoa DP, Passos GAS, Reis RMV, Marques MMC. Identification of Cell-Free Circulating MicroRNAs for the Detection of Early Breast Cancer and Molecular Subtyping. J Oncol 2019;2019:8393769. [PMID: 31485228 DOI: 10.1155/2019/8393769] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
144 Moody L, Chen H, Pan YX. Considerations for feature selection using gene pairs and applications in large-scale dataset integration, novel oncogene discovery, and interpretable cancer screening. BMC Med Genomics 2020;13:148. [PMID: 33087122 DOI: 10.1186/s12920-020-00778-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
145 Hammarsten P, Josefsson A, Thysell E, Lundholm M, Hägglöf C, Iglesias-Gato D, Flores-Morales A, Stattin P, Egevad L, Granfors T, Wikström P, Bergh A. Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome. Mod Pathol 2019;32:1310-9. [PMID: 30980038 DOI: 10.1038/s41379-019-0260-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
146 Tutzauer J, Sjöström M, Bendahl PO, Rydén L, Fernö M, Leeb-Lundberg LMF, Alkner S. Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer. PLoS One 2020;15:e0231786. [PMID: 32302351 DOI: 10.1371/journal.pone.0231786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
147 Montenegro F, Indraccolo S. Metabolism in the Tumor Microenvironment. Adv Exp Med Biol 2020;1263:1-11. [PMID: 32588319 DOI: 10.1007/978-3-030-44518-8_1] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
148 Moudi M, Saravani R, Sargazi S. Silencing of Nucleostemin by siRNA Induces Apoptosis in MCF-7 and MDA-MB-468 Cell Lines. Iran J Pharm Res 2020;19:37-45. [PMID: 32922467 DOI: 10.22037/ijpr.2020.1100950] [Reference Citation Analysis]
149 Aguirre U, García-Gutiérrez S, Romero A, Domingo L, Castells X, Sala M; CAMISS Study Group. External validation of the PREDICT tool in Spanish women with breast cancer participating in population-based screening programmes. J Eval Clin Pract 2019;25:873-80. [PMID: 30548721 DOI: 10.1111/jep.13084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
150 Sughayer MA, Alhassoon S, Sughayer HM. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx. Ann Diagn Pathol 2020;47:151556. [PMID: 32592992 DOI: 10.1016/j.anndiagpath.2020.151556] [Reference Citation Analysis]
151 Dieci MV, Guarneri V, Zustovich F, Mion M, Morandi P, Bria E, Merlini L, Bullian P, Oliani C, Gori S, Giarratano T, Orvieto E, Griguolo G, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P; Veneto Oncology Network. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. Oncologist 2019;24:1424-31. [PMID: 31152079 DOI: 10.1634/theoncologist.2019-0103] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
152 Louie AD, Huntington K, Carlsen L, Zhou L, El-Deiry WS. Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics. Front Pharmacol 2021;12:747194. [PMID: 34737704 DOI: 10.3389/fphar.2021.747194] [Reference Citation Analysis]
153 Lopes BC, Braga CZ, Ventura FV, de Oliveira JG, Kato-Junior EM, Bordin-Junior NA, Zuccari DAPC. miR-210 and miR-152 as Biomarkers by Liquid Biopsy in Invasive Ductal Carcinoma. J Pers Med 2021;11:31. [PMID: 33419057 DOI: 10.3390/jpm11010031] [Reference Citation Analysis]
154 Zheng S, Li M, Li H, Li C, Li P, Qian L, Yang B. Sandwich-type electrochemical immunosensor for carcinoembryonic antigen detection based on the cooperation of a gold-vertical graphene electrode and gold@silica-methylene blue. J Mater Chem B 2020;8:298-307. [PMID: 31808501 DOI: 10.1039/c9tb01803d] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
155 Martínez-Montiel N, Anaya-Ruiz M, Pérez-Santos M, Martínez-Contreras RD. Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools. Genes (Basel) 2017;8:E217. [PMID: 28981467 DOI: 10.3390/genes8100217] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
156 Chen YC, Chang SC, Huang YH, Lee YJ, Chang CC, Liao JW, Hsu WL. Expression and the molecular forms of neutrophil gelatinase-associated lipocalin and matrix metalloproteinase 9 in canine mammary tumours. Vet Comp Oncol 2019;17:427-38. [PMID: 31050171 DOI: 10.1111/vco.12488] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
157 Arnli MB, Winther TL, Lydersen S, Torp SH. Prognostic value of ErbB2/HER2 in human meningiomas. PLoS One 2018;13:e0205846. [PMID: 30335819 DOI: 10.1371/journal.pone.0205846] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
158 Jiang J, Pan W, Xu Y, Ni C, Xue D, Chen Z, Chen W, Huang J. Tumour-Infiltrating Immune Cell-Based Subtyping and Signature Gene Analysis in Breast Cancer Based on Gene Expression Profiles. J Cancer 2020;11:1568-83. [PMID: 32047563 DOI: 10.7150/jca.37637] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
159 Giridhar KV, Liu MC. Available and emerging molecular markers in the clinical management of breast cancer. Expert Rev Mol Diagn 2019;19:919-28. [PMID: 31498011 DOI: 10.1080/14737159.2019.1664901] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
160 Jacob L, Witteveen A, Beumer I, Delahaye L, Wehkamp D, van den Akker J, Snel M, Chan B, Floore A, Bakx N, Brink G, Poncet C, Bogaerts J, Delorenzi M, Piccart M, Rutgers E, Cardoso F, Speed T, van 't Veer L, Glas A. Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial. Commun Biol 2020;3:397. [PMID: 32719399 DOI: 10.1038/s42003-020-1111-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Thompson JA, Christensen BC, Marsit CJ. Methylation-to-Expression Feature Models of Breast Cancer Accurately Predict Overall Survival, Distant-Recurrence Free Survival, and Pathologic Complete Response in Multiple Cohorts. Sci Rep 2018;8:5190. [PMID: 29581450 DOI: 10.1038/s41598-018-23494-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
162 Pondé NF, Zardavas D, Piccart M. Progress in adjuvant systemic therapy for breast cancer. Nat Rev Clin Oncol 2019;16:27-44. [PMID: 30206303 DOI: 10.1038/s41571-018-0089-9] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 21.3] [Reference Citation Analysis]
163 Cserni G, Chmielik E, Cserni B, Tot T. The new TNM-based staging of breast cancer. Virchows Arch 2018;472:697-703. [PMID: 29380126 DOI: 10.1007/s00428-018-2301-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 12.0] [Reference Citation Analysis]
164 Vermeulen MA, van Deurzen CHM, Doebar SC, de Leng WWJ, Martens JWM, van Diest PJ, Moelans CB. Promoter hypermethylation in ductal carcinoma in situ of the male breast. Endocr Relat Cancer 2019;26:575-84. [PMID: 30921768 DOI: 10.1530/ERC-18-0485] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
165 Barba D, León-Sosa A, Lugo P, Suquillo D, Torres F, Surre F, Trojman L, Caicedo A. Breast cancer, screening and diagnostic tools: All you need to know. Crit Rev Oncol Hematol 2021;157:103174. [PMID: 33249359 DOI: 10.1016/j.critrevonc.2020.103174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
166 Stachs A, Hartmann S, Gerber B. Preservation of Fertility or Ovarian Function in Patients with Breast Cancer or Gynecologic and Internal Malignancies. Geburtshilfe Frauenheilkd 2017;77:861-9. [PMID: 28845050 DOI: 10.1055/s-0043-116222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
167 Smith JR, Pe'er J, Belfort RN, Cardoso F, Carvajal RD, Carvalho C, Coupland SE, Desjardins L, Francis JH, Gallie BL, Gombos DS, Grossniklaus HE, Heegaard S, Jager MJ, Kaliki S, Ksander BR, Maeurer M, Moreno E, Pulido JS, Ryll B, Singh AD, Zhao J, Parreira A, Wilson DJ, O'Brien JM. Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference. Transl Vis Sci Technol 2019;8:9. [PMID: 30652059 DOI: 10.1167/tvst.8.1.9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
168 Asleh K, Lyck Carstensen S, Tykjaer Jørgensen CL, Burugu S, Gao D, Won JR, Jensen MB, Balslev E, Laenkholm AV, Nielsen DL, Ejlertsen B, Nielsen TO. Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial. Int J Cancer 2019;144:2578-86. [PMID: 30411790 DOI: 10.1002/ijc.31969] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
169 Nguyen TH, Nguyen VH, Nguyen TL, Qiuyin C, Phung TH. Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients. Biomed Res Int 2019;2019:7391237. [PMID: 31583246 DOI: 10.1155/2019/7391237] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
170 Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin Oncol 2018;36:1941-8. [PMID: 29676944 DOI: 10.1200/JCO.2017.76.4258] [Cited by in Crossref: 53] [Cited by in F6Publishing: 28] [Article Influence: 13.3] [Reference Citation Analysis]
171 Fichtali K, Bititi A, Elghanmi A, Ghazi B. Serum Lipidomic Profiling in Breast Cancer to Identify Screening, Diagnostic, and Prognostic Biomarkers. Biores Open Access 2020;9:1-6. [PMID: 32042507 DOI: 10.1089/biores.2018.0022] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
172 Mathews JC, Nadeem S, Levine AJ, Pouryahya M, Deasy JO, Tannenbaum A. Robust and interpretable PAM50 reclassification exhibits survival advantage for myoepithelial and immune phenotypes. NPJ Breast Cancer 2019;5:30. [PMID: 31531391 DOI: 10.1038/s41523-019-0124-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
173 Geffen DB. Should decisions on adding adjuvant chemotherapy in early-stage ER-positive breast cancer be based on gene expression testing or clinicopathologic factors or both? Ann Oncol 2018;29:1096-8. [PMID: 29635411 DOI: 10.1093/annonc/mdy115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
174 Stevanovic L, Choschzick M, Moskovszky L, Varga Z. Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015-2018. J Cancer Res Clin Oncol 2019;145:2983-94. [PMID: 31628534 DOI: 10.1007/s00432-019-03057-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
175 Reix N, Lodi M, Jankowski S, Molière S, Luporsi E, Leblanc S, Scheer L, Ibnouhsein I, Benabu JC, Gabriele V, Guggiola A, Lessinger JM, Chenard MP, Alpy F, Bellocq JP, Neuberger K, Tomasetto C, Mathelin C. A novel machine learning-derived decision tree including uPA/PAI-1 for breast cancer care. Clin Chem Lab Med 2019;57:901-10. [PMID: 30838840 DOI: 10.1515/cclm-2018-1065] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
176 Latif A, Issa Khan M, Rakha A, Ali Khan J. Evaluating the therapeutic potential of white button mushroom (Agaricus bisporus) against DMBA-induced breast cancer in Sprague Dawley rats. J Food Biochem 2021;:e13979. [PMID: 34698374 DOI: 10.1111/jfbc.13979] [Reference Citation Analysis]
177 Wu L, Yang X. Targeting the Hippo Pathway for Breast Cancer Therapy. Cancers (Basel) 2018;10:E422. [PMID: 30400599 DOI: 10.3390/cancers10110422] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 9.8] [Reference Citation Analysis]
178 Hannouf MB, Zaric GS, Blanchette P, Brezden-Masley C, Paulden M, McCabe C, Raphael J, Brackstone M. Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer. Pharmacogenomics J 2020;20:27-46. [PMID: 31130722 DOI: 10.1038/s41397-019-0089-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
179 Pereira A, Sales M, Rodrigues L. Biosensors for Rapid Detection of Breast Cancer Biomarkers. Advanced Biosensors for Health Care Applications. Elsevier; 2019. pp. 71-103. [DOI: 10.1016/b978-0-12-815743-5.00003-2] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
180 Lv W, Shen Y, Yang H, Yang R, Cai W, Zhang J, Yuan L, Duan Y, Zhang L. A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast Cancer. J Immunol Res 2018;2018:6202876. [PMID: 29854844 DOI: 10.1155/2018/6202876] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
181 Beato Tortajada I, Ferrer Albiach C, Morillo Macias V. Nomogram for the personalisation of radiotherapy treatments in breast cancer patients. Breast 2021;60:255-62. [PMID: 34808437 DOI: 10.1016/j.breast.2021.11.004] [Reference Citation Analysis]
182 Voith von Voithenberg L, Crocetti E, Martos C, Dimitrova N, Giusti F, Randi G, Rooney R, Dyba T, Bettio M, Negrão Carvalho R. Cancer registries - guardians of breast cancer biomarker information: A systematic review. Int J Biol Markers 2019;34:194-9. [PMID: 30968746 DOI: 10.1177/1724600819836097] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
183 Zeng N, Liao N, Han C, Liu W, Gao Z. Leveraging Fitness Tracker and Personalized Exercise Prescription to Promote Breast Cancer Survivors' Health Outcomes: A Feasibility Study. J Clin Med 2020;9:E1775. [PMID: 32521652 DOI: 10.3390/jcm9061775] [Reference Citation Analysis]
184 Zhou Z, McDougald D, Devoogdt N, Zalutsky MR, Vaidyanathan G. Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[18F]Fluoronicotinate Resulting in High Tumor-to-Kidney Ratios. Mol Pharm 2019;16:214-26. [PMID: 30427188 DOI: 10.1021/acs.molpharmaceut.8b00951] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
185 Jevrić M, Matić IZ, Krivokuća A, Đorđić Crnogorac M, Besu I, Damjanović A, Branković-Magić M, Milovanović Z, Gavrilović D, Susnjar S, Kisić Tepavčević D, Stanojković T. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy. BMC Cancer 2019;19:71. [PMID: 30646864 DOI: 10.1186/s12885-018-5255-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
186 Viale G, Hanlon Newell AE, Walker E, Harlow G, Bai I, Russo L, Dell'Orto P, Maisonneuve P. Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes. Breast Cancer Res Treat 2019;178:451-8. [PMID: 31422497 DOI: 10.1007/s10549-019-05402-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
187 Xie Q, Xiao YS, Jia SC, Zheng JX, Du ZC, Chen YC, Chen MT, Liang YK, Lin HY, Zeng. FABP7 is a potential biomarker to predict response to neoadjuvant chemotherapy for breast cancer. Cancer Cell Int 2020;20:562. [PMID: 33292226 DOI: 10.1186/s12935-020-01656-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
188 Wei C, Li X. Verteporfin inhibits cell proliferation and induces apoptosis in different subtypes of breast cancer cell lines without light activation. BMC Cancer 2020;20:1042. [PMID: 33121449 DOI: 10.1186/s12885-020-07555-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
189 Zhang J, Wei Q, Dong D, Ren L. The role of TPS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer. Clin Chim Acta 2021;523:19-25. [PMID: 34454906 DOI: 10.1016/j.cca.2021.08.027] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
190 Alfarsi LH, El Ansari R, Craze ML, Masisi BK, Ellis IO, Rakha EA, Green AR. PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer. BMC Cancer 2020;20:425. [PMID: 32410585 DOI: 10.1186/s12885-020-06939-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
191 Martínez-Pérez C, Kay C, Meehan J, Gray M, Dixon JM, Turnbull AK. The IL6-like Cytokine Family: Role and Biomarker Potential in Breast Cancer. J Pers Med 2021;11:1073. [PMID: 34834425 DOI: 10.3390/jpm11111073] [Reference Citation Analysis]
192 van Dooijeweert C, Baas IO, Deckers IAG, Siesling S, van Diest PJ, van der Wall E. The increasing importance of histologic grading in tailoring adjuvant systemic therapy in 30,843 breast cancer patients. Breast Cancer Res Treat 2021;187:577-86. [PMID: 33517555 DOI: 10.1007/s10549-021-06098-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
193 Abouelghar A, Hasnah R, Taouk G, Saad M, Karam M. Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients. Oncotarget 2018;9:27171-96. [PMID: 29930758 DOI: 10.18632/oncotarget.25506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
194 Nittala MR, Mundra EK, Packianathan S, Mehta D, Smith ML, Woods WC, McKinney S, Craft BS, Vijayakumar S. The Will Rogers phenomenon, breast cancer and race. BMC Cancer 2021;21:554. [PMID: 34001038 DOI: 10.1186/s12885-021-08125-8] [Reference Citation Analysis]
195 Al-Mughales JA, Alahwal MS. Inappropriate practice in tumor marker requests at a university hospital in Western Saudi Arabia: A 3-year retrospective study. Int J Biol Markers 2020;35:35-43. [PMID: 33158390 DOI: 10.1177/1724600820971305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
196 Thysell E, Vidman L, Ylitalo EB, Jernberg E, Crnalic S, Iglesias-Gato D, Flores-Morales A, Stattin P, Egevad L, Widmark A, Rydén P, Bergh A, Wikström P. Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor. Mol Oncol 2019;13:1763-77. [PMID: 31162796 DOI: 10.1002/1878-0261.12526] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
197 Caruana E, Foucher Y, Tessier P, Frenel JS, Classe JM, Dantan E. Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer. Breast Cancer Res Treat 2019;174:537-42. [PMID: 30603997 DOI: 10.1007/s10549-018-05107-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
198 Lu Y, Tong Y, Chen X, Shen K. Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients. Front Oncol 2021;11:638619. [PMID: 34277399 DOI: 10.3389/fonc.2021.638619] [Reference Citation Analysis]
199 Ni H, Kumbrink J, Mayr D, Seiler A, Hagemann F, Degenhardt T, Sagebiel S, Würstlein R, Kates R, Harbeck N, Eggersmann TK. Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2- Early Breast Cancer. J Pers Med 2021;11:835. [PMID: 34575612 DOI: 10.3390/jpm11090835] [Reference Citation Analysis]
200 Nigdelis MP, Karamouzis MV, Kontos M, Alexandrou A, Goulis DG, Lambrinoudaki I. Updates on the treatment of invasive breast cancer: Quo Vadimus? Maturitas 2021;145:64-72. [PMID: 33541565 DOI: 10.1016/j.maturitas.2020.11.006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
201 Huang RSP, Li X, Haberberger J, Sokol E, Severson E, Duncan DL, Hemmerich A, Edgerly C, Williams E, Elvin J, Vergilio JA, Killian JK, Lin D, Hiemenz M, Xiao J, McEwan D, Holmes O, Danziger N, Erlich R, Frampton G, Cohen MB, McGregor K, Reddy P, Cardeiro D, Anhorn R, Venstrom J, Alexander B, Brown C, Pusztai L, Ross JS, Ramkissoon SH. Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. Oncologist 2020;25:943-53. [PMID: 32869930 DOI: 10.1634/theoncologist.2020-0449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
202 Cook DJ, Kallus J, Jörnsten R, Nielsen J. Molecular natural history of breast cancer: Leveraging transcriptomics to predict breast cancer progression and aggressiveness. Cancer Med 2020;9:3551-62. [PMID: 32207233 DOI: 10.1002/cam4.2996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
203 Ha JH, Hong KY, Lee HB, Moon HG, Han W, Noh DY, Lim J, Yoon S, Chang H, Jin US. Oncologic outcomes after immediate breast reconstruction following mastectomy: comparison of implant and flap using propensity score matching. BMC Cancer 2020;20:78. [PMID: 32000718 DOI: 10.1186/s12885-020-6568-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
204 Pereira BTL, Gonçalves MA, Mancini DT, Kuca K, Ramalho TC. First Attempts of the Use of 195Pt NMR of Phenylbenzothiazole Complexes as Spectroscopic Technique for the Cancer Diagnosis. Molecules 2019;24:E3970. [PMID: 31684009 DOI: 10.3390/molecules24213970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
205 Wenric S, ElGuendi S, Caberg JH, Bezzaou W, Fasquelle C, Charloteaux B, Karim L, Hennuy B, Frères P, Collignon J, Boukerroucha M, Schroeder H, Olivier F, Jossa V, Jerusalem G, Josse C, Bours V. Transcriptome-wide analysis of natural antisense transcripts shows their potential role in breast cancer. Sci Rep 2017;7:17452. [PMID: 29234122 DOI: 10.1038/s41598-017-17811-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
206 Caselli E, Pelliccia C, Teti V, Bellezza G, Mandarano M, Ferri I, Hartmann K, Laible M, Sahin U, Varga Z, Lupi C, Stracci F, Sidoni A. Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR. PLoS One 2021;16:e0255580. [PMID: 34555047 DOI: 10.1371/journal.pone.0255580] [Reference Citation Analysis]
207 Lepola A, Arponen O, Okuma H, Holli-Helenius K, Junkkari H, Könönen M, Auvinen P, Sudah M, Sutela A, Vanninen R. Association between breast cancer's prognostic factors and 3D textural features of non-contrast-enhanced T1 weighted breast MRI. Br J Radiol 2021;:20210702. [PMID: 34826254 DOI: 10.1259/bjr.20210702] [Reference Citation Analysis]
208 Liu XP, Hou J, Chen C, Guan L, Hu HK, Li S. A DNA Methylation-Based Panel for the Prognosis and Dagnosis of Patients With Breast Cancer and Its Mechanisms. Front Mol Biosci 2020;7:118. [PMID: 32733914 DOI: 10.3389/fmolb.2020.00118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
209 Colomer R, Aranda-López I, Albanell J, García-Caballero T, Ciruelos E, López-García MÁ, Cortés J, Rojo F, Martín M, Palacios-Calvo J. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol 2018;20:815-26. [PMID: 29273958 DOI: 10.1007/s12094-017-1800-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
210 Yu L, Zhao L, Jia Z, Bi J, Wei Q, Song X, Jiang L, Lin S, Wei M. MFG-E8 overexpression is associated with poor prognosis in breast cancer patients. Pathol Res Pract 2019;215:490-8. [PMID: 30612778 DOI: 10.1016/j.prp.2018.12.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
211 Vlajnic T, Bubendorf L. Molecular pathology of prostate cancer: a practical approach. Pathology 2021;53:36-43. [PMID: 33234230 DOI: 10.1016/j.pathol.2020.10.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]